Review
Version 6
Preserved in Portico This version is not peer-reviewed
A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations
Version 1
: Received: 21 August 2023 / Approved: 21 August 2023 / Online: 22 August 2023 (07:58:07 CEST)
Version 2 : Received: 5 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (02:54:00 CEST)
Version 3 : Received: 31 December 2023 / Approved: 2 January 2024 / Online: 2 January 2024 (10:00:17 CET)
Version 4 : Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (13:52:59 CET)
Version 5 : Received: 21 March 2024 / Approved: 22 March 2024 / Online: 22 March 2024 (12:06:13 CET)
Version 6 : Received: 9 May 2024 / Approved: 9 May 2024 / Online: 9 May 2024 (10:33:03 CEST)
Version 2 : Received: 5 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (02:54:00 CEST)
Version 3 : Received: 31 December 2023 / Approved: 2 January 2024 / Online: 2 January 2024 (10:00:17 CET)
Version 4 : Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (13:52:59 CET)
Version 5 : Received: 21 March 2024 / Approved: 22 March 2024 / Online: 22 March 2024 (12:06:13 CET)
Version 6 : Received: 9 May 2024 / Approved: 9 May 2024 / Online: 9 May 2024 (10:33:03 CEST)
How to cite: Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints 2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v6 Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints 2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v6
Abstract
Recently concluded, large-scale cancer genomics studies involving multiregion sequencing of primary tumors and paired metastases appear to indicate that many or most cancer patients have one or more “clonal" mutations in their tumors. Clonal mutations are those that are present in all of a patient’s cancer cells. Achilles Therapeutics is currently the only company specifically targeting clonal mutations. However, they are doing so with tumor-derived T cells. To address the potential limitations of immunotherapy, I have devised another approach for exploiting clonal mutations, which I call “Oncolytic Vector Efficient Replication Contingent on Omnipresent Mutation Engagement” (OVERCOME). The ideal version of OVERCOME would likely employ a bioengineered facultative intracellular bacterium. The bacterium would initially be attenuated, but (transiently) reverse its attenuation upon clonal mutation detection.
Keywords
multiregion sequencing; multisample sequencing; cell-free circulating tumor DNA; clonal mutations; Achilles Therapeutics; OVERCOME
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment